Insulin Glargine Market, By Type (Lantus, Basaglar, Toujeo, Soliqua/Suliqua, Others), By Diabetes Type (Type 2 Diabetes, Type 1 Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, La

Insulin Glargine Market, By Type (Lantus, Basaglar, Toujeo, Soliqua/Suliqua, Others), By Diabetes Type (Type 2 Diabetes, Type 1 Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Insulin glargine, also known as Lantus, is a long-acting basal insulin that is used for the treatment of diabetes mellitus. It is a synthetic form of human insulin created through recombinant DNA technology, engineered to be soluble in acidic environments. Upon injection, it precipitates and forms microcrystals in the subcutaneous tissue, creating a depot from which insulin is gradually absorbed into the bloodstream. This extended release and duration of action profile allows once-daily dosing to help control blood glucose levels in patients with type 1 and type 2 diabetes over 24 hours. Insulin glargine has a slower absorption profile as compared to other basal insulins such as insulin detemir and insulin NPH, and thus, provides a smooth and consistent level of insulin in the blood.

Market Dynamics:

Global insulin glargine market growth is driven by growing prevalence of diabetes worldwide. According to estimates by the International Diabetes Federation 2021, over 537 million adults lived with diabetes in 2021, and the number is projected to rise to 643 million by 2030 and 783 million by 2045. Increasing geriatric population also contributes to market growth since diabetes is more common in older age groups. However, cost constraints, especially in developing countries, acts as a restrain. On the positive side, ongoing development of more effective and convenient drug delivery technologies is expected to present new opportunities.

Key Features of the Study:

• This report provides in-depth analysis of the global insulin glargine market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global insulin glargine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes Sanofi, Biocon, Eli Lilly and Company, Boehringer Ingelheim, Gan & Lee, Kalbe Pharma, Polus Biopharm, Samsung Bioepis, Wockhardt, Novo Nordisk AS, Julphar, and Viatris Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global insulin glargine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin glargine market.

Detailed Segmentation

• Type:
• Lantus
• Basaglar
• Toujeo
• Soliqua/Suliqua
• Others
• Diabetes Type:
• Type 2 Diabetes
• Type 1 Diabetes
• Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
• Company Profiles:
• Sanofi
• Biocon
• Eli Lilly and Company
• Boehringer Ingelheim
• Gan & Lee
• Kalbe Pharma
• Polus Biopharm
• Samsung Bioepis
• Wockhardt
• Novo Nordisk AS
• Julphar
• Viatris Inc.